TRAVERSA SERGIO

CEO Traversa buys 27,500 RLMD shares at $4.12; 4 of 4 prior same-ticker purchases were well-timed, with 90d returns of +92.7% to +593.6%.

Sergio Traversa, the CEO, purchased 27,500 shares at $4.12 on 2025-12-15 for $113,300.00, bringing his holdings to 1.30M shares. His same-ticker trade history at RLMD is exceptional: four prior purchases (on 2025-08-26, 2025-08-27, 2025-08-28, and 2025-11-05) all registered positive 90-day returns, with outcomes ranging from +92.7% to +593.6%, and the earlier three clustered in August all exceeded +466% at the 90-day mark. This pattern—a 100% well-timed track record at this ticker across measurable intervals—stands in sharp contrast to the company's fundamentals: annual revenue declined 35.4%, the company posted a net loss of $-10.1M in its most recent full fiscal year, and the latest quarter generated only $682.00 in revenue. The buy occurs at $4.12, well within the 52-week range ($0.25–$4.51) and currently 0.2% below the 52-week high of $4.51, after a 30-day surge of +13.9% and a 90-day spike of +198.0%. The repeated, consistently well-timed purchases at depressed valuations amid deteriorating financials warrant close monitoring of what information or operational catalyst the CEO may be observing.

RLMD CEO Traversa buys 272,500 shares at $2.20 (11/5/25); 27.2% stake increase amid cluster buy; unprofitable firm with -35.4% revenue decline

CEO Sergio Traversa purchased 272,500 shares at $2.20 on 2025-11-05, increasing his holdings by 27.2% to 1,272,500 shares total—a significant concentration move by the company's chief executive. This buy occurs within a 14-day window when 3 other insiders also purchased, signaling a coordinated insider accumulation pattern. Relmada's fundamentals remain deeply concerning: the company reported quarterly revenue of $682.00, negative annual net income of $-9,866,442.00, and year-over-year revenue contraction of -35.4%, indicating ongoing operational distress. Traversa's prior trades at RLMD show measurable 90-day outcomes on 2 historical buys, both posting positive 90-day returns, though his broader cross-ticker track record is mixed (12 prior buys averaging -20.2% over 90 days with a 44.44% win rate), suggesting his timing ability at this specific ticker does not extrapolate to his general record.

Relmada CEO Traversa buys 265,976 shares across 3 days for $178,094.99; holdings jump +36.2% to 1,000,000 shares

Sergio Traversa, CEO of Relmada Therapeutics (unprofitable, -35.4% annual revenue decline, $25.9M market cap), executed 3 separate purchases totaling 265,976 shares for $178,094.99 at prices ranging from $0.62 to $0.74 on Aug 26–28, 2025. This increased his holdings by 36.2% from 734,024 to 1,000,000 shares, a material position expansion. The timing coincides with a 24.7% 30-day price run (+$0.53 from prior lows to current $0.78), though the stock remains -78.6% below its 52-week high of $3.64. Traversa's recent same-ticker purchase history shows mixed outcomes: his May 2025 buys achieved +25.7% to +55.7% 90-day returns, but earlier buys in September 2024 resulted in -82.5% and -84.3% declines. The concentrated three-day sequence and aggressive share accumulation in a micro-cap therapeutics company trading near its 52-week lows warrant close attention to company-specific catalysts or financial health signals that may have prompted this expansion.

CEO Traversa buys 350.0K shares in 3 transactions at $0.45–$0.56, averaging $0.50; holdings +91.1% to 734.0K shares amid stock -86.2% from 52-week high.

Sergio Traversa, CEO of Relmada Therapeutics, executed 3 separate open-market purchases totaling 350,000 shares for $174,712.70 between May 16–20, 2025, at prices ranging from $0.45 to $0.56, with a blended average of $0.50. This represents a 91.1% increase in his holdings to 734,024 shares. The stock has declined 86.2% from its 52-week high of $4.36 to a current price of $0.60, though it has gained 107.0% over the past 30 days and 82.9% over 90 days. At the same ticker, Traversa's prior 5 buys show a consistent pattern: 0 of 5 achieved positive 90-day returns, with declines ranging from -83.1% to -84.3% in the September 2024 cluster. The company is unprofitable with a net loss of $17,559,465 over its most recent full fiscal year, annual revenue growth of -35.4%, and a market cap of $19,914,973.20. A cluster buy pattern is present with 3 other insiders also purchasing within the past 14 days, though this does not indicate coordinated action by the CEO himself. The persistence of insider buying amid deteriorating fundamentals and the insider's historical poor 90-day outcomes at this ticker warrant detailed examination of the underlying strategic rationale.

CEO Traversa bought 140,000 shares ($395.1K) over 3 days at $2.71–$2.99; cluster activity amid -35.4% revenue decline

Sergio Traversa, Chief Executive Officer, executed 3 separate purchases totaling 140,000 shares for $395,114.52 at a blended average price of $2.82 over September 9–11, 2024, increasing his holdings by 57.4% from 244.0K to 384.0K shares. This multi-day accumulation occurred alongside purchases by 3 other insiders within the same 14-day window, forming a cluster pattern. The timing occurs in a challenged context: Relmada reported -35.4% annual revenue decline, unprofitability ($-17.8M net loss), a market cap of only $91.1M, and the stock currently trades at -55.6% from its 52-week high, though up 31.3% over the prior 30 days. At this ticker, Traversa's prior 3 buys (January 2024) showed mixed 90-day outcomes (two negative, one slightly positive at +3.2%), establishing a 33.33% win rate historically on this company. The cluster pattern and CEO-led accumulation warrant examination of underlying catalysts or strategic positioning, given the company's significant revenue contraction and negative profitability.